Amgen (AMGN) Other financing activities (2009 - 2026)
Amgen's quarterly Other financing activities came in at -$104.0 million in Q1 2026, down 285.19% year-on-year from $56.2 million in Q1 2025, and down 282.46% quarter-over-quarter from $57.0 million in Q4 2025.
Amgen has reported Other financing activities for 18 years, with the latest figure at -$104.0 million in Q1 2026.
- For the quarter ending Q1 2026, Other financing activities fell 285.19% year-over-year to -$104.0 million; the trailing twelve-month figure through Mar 2026 stood at -$129.0 million (down 111.48% YoY), and the FY2025 full-year result was -$52.0 million, up 58.06% from the prior year.
- Other financing activities for Q1 2026 stood at -$104.0 million, down from $57.0 million in the prior quarter.
- The five-year high for Other financing activities was $57.0 million in Q4 2025, with the low at -$104.0 million in Q1 2026.
- Average Other financing activities over 5 years is -$26.8 million, with a median of -$26.0 million recorded in 2022.
- Year-over-year, Other financing activities jumped 2950.0% in 2025 and tumbled 285.19% in 2026.
- Tracing AMGN's Other financing activities over 5 years: stood at $10.0 million in 2022, then slumped by 150.0% to -$5.0 million in 2023, then surged by 60.0% to -$2.0 million in 2024, then jumped by 2950.0% to $57.0 million in 2025, then tumbled by 282.46% to -$104.0 million in 2026.
- The last three Other financing activities figures came in at -$104.0 million (Q1 2026), $57.0 million (Q4 2025), and $10.0 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Novartis Ag | 107,124,802.25 Bn | 107,124,802.25 Bn | - |
| 2 | Eli Lilly | 969.00 Bn | 963.72 Bn | 16.22 Bn |
| 3 | Johnson & Johnson | 539.46 Bn | 517.41 Bn | 15.96 Bn |
| 4 | AbbVie | 376.92 Bn | 367.57 Bn | 10.78 Bn |
| 5 | Merck | 285.00 Bn | 279.35 Bn | 12.09 Bn |
| 6 | Amgen | 177.58 Bn | 165.55 Bn | 5.87 Bn |
| 7 | Gilead Sciences | 163.22 Bn | 155.50 Bn | 5.52 Bn |
| 8 | Pfizer | 145.86 Bn | 133.09 Bn | -1.21 Bn |
| 9 | Bristol Myers Squibb | 111.90 Bn | 101.44 Bn | 8.07 Bn |
| 10 | Gsk | 88.34 Bn | 83.66 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -104.00 Mn |
| Mar 31, 2026 | -104.00 Mn |
| Dec 31, 2025 | 57.00 Mn |
| Dec 31, 2025 | 57.00 Mn |
| Sep 30, 2025 | 10.00 Mn |
| Sep 30, 2025 | 10.00 Mn |
| Jun 30, 2025 | -92.00 Mn |
| Jun 30, 2025 | -92.00 Mn |
| Mar 31, 2025 | -27.00 Mn |
| Mar 31, 2025 | -27.00 Mn |
| Dec 31, 2024 | -2.00 Mn |
| Dec 31, 2024 | -2.00 Mn |
| Sep 30, 2024 | 8.00 Mn |
| Sep 30, 2024 | 8.00 Mn |
| Jun 30, 2024 | -40.00 Mn |
| Jun 30, 2024 | -40.00 Mn |
| Mar 31, 2024 | -90.00 Mn |
| Mar 31, 2024 | -90.00 Mn |
| Dec 31, 2023 | -5.00 Mn |
| Dec 31, 2023 | -5.00 Mn |
| Sep 30, 2023 | 14.00 Mn |
| Sep 30, 2023 | 14.00 Mn |
| Jun 30, 2023 | -53.00 Mn |
| Jun 30, 2023 | -53.00 Mn |
| Mar 31, 2023 | -28.00 Mn |
| Mar 31, 2023 | -28.00 Mn |
| Dec 31, 2022 | 10.00 Mn |
| Dec 31, 2022 | 10.00 Mn |
| Sep 30, 2022 | -61.00 Mn |
| Sep 30, 2022 | -61.00 Mn |
| Jun 30, 2022 | -26.00 Mn |
| Jun 30, 2022 | -26.00 Mn |
| Mar 31, 2022 | -26.00 Mn |
| Mar 31, 2022 | -26.00 Mn |
| Dec 31, 2021 | 26.00 Mn |
| Dec 31, 2021 | 26.00 Mn |
| Sep 30, 2021 | -19.00 Mn |
| Sep 30, 2021 | -19.00 Mn |
| Jun 30, 2021 | -33.00 Mn |
| Jun 30, 2021 | -33.00 Mn |
| Mar 31, 2021 | -52.00 Mn |
| Mar 31, 2021 | -52.00 Mn |
| Dec 31, 2020 | -3.00 Mn |
| Dec 31, 2020 | -3.00 Mn |
| Sep 30, 2020 | -9.00 Mn |
| Sep 30, 2020 | -9.00 Mn |
| Jun 30, 2020 | -17.00 Mn |
| Jun 30, 2020 | -17.00 Mn |
| Mar 31, 2020 | -61.00 Mn |
| Mar 31, 2020 | -61.00 Mn |
| Dec 31, 2019 | 25.00 Mn |
| Dec 31, 2019 | 25.00 Mn |
| Sep 30, 2019 | 34.00 Mn |
| Sep 30, 2019 | 34.00 Mn |
| Jun 30, 2019 | -47.00 Mn |
| Jun 30, 2019 | -47.00 Mn |
| Mar 31, 2019 | -54.00 Mn |
| Mar 31, 2019 | -54.00 Mn |
| Dec 31, 2018 | 17.00 Mn |
| Dec 31, 2018 | 17.00 Mn |
| Jun 30, 2018 | -41.00 Mn |
| Jun 30, 2018 | -41.00 Mn |
| Mar 31, 2018 | -44.00 Mn |
| Mar 31, 2018 | -44.00 Mn |
| Dec 31, 2017 | 188.00 Mn |
| Dec 31, 2017 | 188.00 Mn |
| Jun 30, 2017 | -64.00 Mn |
| Jun 30, 2017 | -64.00 Mn |
| Mar 31, 2017 | -73.00 Mn |
| Mar 31, 2017 | -73.00 Mn |
| Dec 31, 2016 | 263.00 Mn |
| Dec 31, 2016 | 263.00 Mn |
| Sep 30, 2016 | 13.00 Mn |
| Sep 30, 2016 | 13.00 Mn |
| Jun 30, 2016 | -116.00 Mn |
| Jun 30, 2016 | -116.00 Mn |
| Mar 31, 2016 | -129.00 Mn |
| Mar 31, 2016 | -129.00 Mn |
| Dec 31, 2015 | 16.00 Mn |
| Dec 31, 2015 | 16.00 Mn |
| Sep 30, 2015 | 14.00 Mn |
| Sep 30, 2015 | 14.00 Mn |
| Jun 30, 2015 | 35.00 Mn |
| Jun 30, 2015 | 35.00 Mn |
| Mar 31, 2015 | 16.00 Mn |
| Mar 31, 2015 | 16.00 Mn |
| Dec 31, 2014 | -151.00 Mn |
| Dec 31, 2014 | -151.00 Mn |
| Sep 30, 2014 | 22.00 Mn |
| Sep 30, 2014 | 22.00 Mn |
| Jun 30, 2014 | 52.00 Mn |
| Jun 30, 2014 | 52.00 Mn |
| Mar 31, 2014 | 52.00 Mn |
| Mar 31, 2014 | 52.00 Mn |
| Dec 31, 2013 | 24.00 Mn |
| Dec 31, 2013 | 24.00 Mn |
| Sep 30, 2013 | 11.00 Mn |
| Sep 30, 2013 | 11.00 Mn |
| Jun 30, 2013 | -48.00 Mn |
| Jun 30, 2013 | -48.00 Mn |
| Mar 31, 2013 | 7.00 Mn |
| Mar 31, 2013 | 7.00 Mn |
| Dec 31, 2012 | 6.00 Mn |
| Dec 31, 2012 | 6.00 Mn |
| Sep 30, 2012 | 14.00 Mn |
| Sep 30, 2012 | 14.00 Mn |
| Jun 30, 2012 | 21.00 Mn |
| Jun 30, 2012 | 21.00 Mn |
| Mar 31, 2012 | 5.00 Mn |
| Mar 31, 2012 | 5.00 Mn |
| Dec 31, 2011 | 4.00 Mn |
| Dec 31, 2011 | 4.00 Mn |
| Sep 30, 2011 | -5.00 Mn |
| Sep 30, 2011 | -5.00 Mn |
| Jun 30, 2011 | 11.00 Mn |
| Jun 30, 2011 | 11.00 Mn |
| Mar 31, 2011 | 2.00 Mn |
| Mar 31, 2011 | 2.00 Mn |
| Dec 31, 2010 | -69.00 Mn |
| Dec 31, 2010 | -69.00 Mn |
| Sep 30, 2010 | 20.00 Mn |
| Sep 30, 2010 | 20.00 Mn |
| Jun 30, 2010 | 56.00 Mn |
| Jun 30, 2010 | 56.00 Mn |
| Mar 31, 2010 | -4.00 Mn |
| Mar 31, 2010 | -4.00 Mn |
| Dec 31, 2009 | 180.00 Mn |
| Dec 31, 2009 | 180.00 Mn |
| Sep 30, 2009 | 6.00 Mn |
| Sep 30, 2009 | 6.00 Mn |
| Jun 30, 2009 | 17.00 Mn |
| Jun 30, 2009 | 17.00 Mn |
| Mar 31, 2009 | 1.00 Mn |
| Mar 31, 2009 | 1.00 Mn |